| Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches JA Welsh, DCI Goberdhan, L O'Driscoll, EI Buzas, C Blenkiron, ... Journal of extracellular vesicles 13 (2), e12404, 2024 | 1010 | 2024 |
| miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts AM Eiring, JG Harb, P Neviani, C Garton, JJ Oaks, R Spizzo, S Liu, ... Cell 140 (5), 652-665, 2010 | 716 | 2010 |
| The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein P Neviani, R Santhanam, R Trotta, M Notari, BW Blaser, S Liu, H Mao, ... Cancer cell 8 (5), 355-368, 2005 | 605 | 2005 |
| Protein phosphatase 2A: a target for anticancer therapy D Perrotti, P Neviani The lancet oncology 14 (6), e229-e238, 2013 | 495 | 2013 |
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia P Neviani, R Santhanam, JJ Oaks, AM Eiring, M Notari, BW Blaser, S Liu, ... The Journal of clinical investigation 117 (9), 2408-2421, 2007 | 437 | 2007 |
| Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells HG Jørgensen, EK Allan, NE Jordanides, JC Mountford, TL Holyoake Blood 109 (9), 4016-4019, 2007 | 397 | 2007 |
| Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy KB Challagundla, PM Wise, P Neviani, H Chava, M Murtadha, T Xu, ... Journal of the National Cancer Institute 107 (7), djv135, 2015 | 391 | 2015 |
| Src homology 2 domain–containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic … S Costinean, SK Sandhu, IM Pedersen, E Tili, R Trotta, D Perrotti, ... Blood, The Journal of the American Society of Hematology 114 (7), 1374-1382, 2009 | 367 | 2009 |
| Natural killer–derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms P Neviani, PM Wise, M Murtadha, CW Liu, CH Wu, AY Jong, RC Seeger, ... Cancer research 79 (6), 1151-1164, 2019 | 277 | 2019 |
| PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells P Neviani, JG Harb, JJ Oaks, R Santhanam, CJ Walker, JJ Ellis, ... The Journal of clinical investigation 123 (10), 4144-4157, 2013 | 267 | 2013 |
| A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation M Notari, P Neviani, R Santhanam, BW Blaser, JS Chang, A Galietta, ... Blood 107 (6), 2507-2516, 2006 | 240 | 2006 |
| Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl MA Gregory, TL Phang, P Neviani, F Alvarez-Calderon, CA Eide, T O'Hare, ... Cancer cell 18 (1), 74-87, 2010 | 215 | 2010 |
| Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease EK Thomas, JA Cancelas, HD Chae, AD Cox, PJ Keller, D Perrotti, ... Cancer cell 12 (5), 467-478, 2007 | 173 | 2007 |
| Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers KG Roberts, AM Smith, F McDougall, H Carpenter, M Horan, P Neviani, ... Cancer research 70 (13), 5438-5447, 2010 | 165 | 2010 |
| Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias CJ Walker, JJ Oaks, R Santhanam, P Neviani, JG Harb, G Ferenchak, ... Blood, The Journal of the American Society of Hematology 122 (17), 3034-3044, 2013 | 160 | 2013 |
| Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1 (+) leukemias D Perrotti, P Neviani Cancer and Metastasis Reviews 27, 159-168, 2008 | 155 | 2008 |
| Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies JJ Oaks, R Santhanam, CJ Walker, S Roof, JG Harb, G Ferenchak, ... Blood, The Journal of the American Society of Hematology 122 (11), 1923-1934, 2013 | 136 | 2013 |
| High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2–dependent suppression of C/EBPα-driven myeloid differentiation JS Chang, R Santhanam, R Trotta, P Neviani, AM Eiring, E Briercheck, ... Blood, The Journal of the American Society of Hematology 110 (3), 994-1003, 2007 | 134 | 2007 |
| Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia AM Dorrance, P Neviani, GJ Ferenchak, X Huang, D Nicolet, KS Maharry, ... Leukemia 29 (11), 2143-2153, 2015 | 127 | 2015 |
| Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells C Guerzoni, M Bardini, SA Mariani, G Ferrari-Amorotti, P Neviani, ... Blood 107 (10), 4080-4089, 2006 | 119 | 2006 |
Perrotti DaniloThe University of Maryland BaltimoreVerified email at som.umaryland.edu
